Evidence map›Paper›PMID 35903754›Full record

ArticleJournal of immunology research2022

Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer.

Nan Jing, Luoyang Wang, Huiren Zhuang, Chao Ai, Guoqiang Jiang, Zheng Liu

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nan JingDepartment of Chemical Engineering, Tsinghua University, 100084 Beijing, China.ORCID https://orcid.org/0000-0002-0081-8473
Luoyang WangSchool of Basic Medicine, Qingdao University, 266071 Qingdao, China.ORCID https://orcid.org/0000-0002-1396-0057
Huiren ZhuangDepartment of Chemical Engineering, Tsinghua University, 100084 Beijing, China.ORCID https://orcid.org/0000-0002-1715-874X
Chao AiBeijing Tsinghua Changgung Hospital, 102218 Beijing, China.
Guoqiang JiangDepartment of Chemical Engineering, Tsinghua University, 100084 Beijing, China.ORCID https://orcid.org/0000-0001-9066-4828
Zheng LiuDepartment of Chemical Engineering, Tsinghua University, 100084 Beijing, China.ORCID https://orcid.org/0000-0002-0240-2121
Tsinghua University · CNBeijing Tsinghua Chang Gung Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colitis is a frequently occurred side effect of immune checkpoint inhibitors (ICIs), which are increasingly used in cancer treatment, whereas antibiotics are widely used to treat colitis, their effectiveness in ICI-associated colitis remains controversial. In this study, we firstly assessed the effectiveness of several commonly used antibiotics and antibiotic cocktails in alleviating of dextran sulfate sodium- (DSS-) induced colitis. We observed that two narrow-spectrum antibiotics, neomycin and metronidazole, were more effective in alleviating colitis, as evidenced by the remission of loss of the body weight, enlargement of the spleen, shortening of the colon, secretion of proinflammatory cytokines, and histological score of the colon tissue. Moreover, these two antibiotics resulted in better relief of colitis symptoms in the MC38 tumor-bearing male mice receiving the anti-PD-L1 mAb (

Indexed as

ColitisColonic NeoplasmsAnimalsAnti-Bacterial AgentsColonCytokinesDisease Models, AnimalFemaleImmunityMaleMetronidazoleMiceNeomycinAnti-Bacterial AgentsCytokinesMetronidazoleNeomycin

Identifiers

PMID35903754
PMCPMC9325566
OpenAlexW4285794265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.